公开(公告)号：US11524992B2

公开(公告)日：2022-12-13

申请号：US16751788

申请日：2020-01-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dasa Lipovsek ,  Joseph Toth ,  Ginger C. Rakestraw ,  Irvith M. Carvajal ,  Stanley Richard Krystek, Jr. ,  Steven R. O'Neil ,  Guodong Chen ,  Richard Y. Huang ,  Bryan C. Barnhart ,  John Thomas Loffredo ,  Christina Terragni

IPC: C07K14/78 ,  A61K47/64 ,  G01N33/68 ,  A61K38/00 ,  A61K47/60

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

公开(公告)号：US20220185856A1

公开(公告)日：2022-06-16

申请号：US17555633

申请日：2021-12-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  Daniel Cohen ,  Ranjan Mukherjee ,  Timothy P. Reilly ,  Rose C. Christian ,  Dasa Lipovsek ,  Ray Camphausen ,  John Krupinski

IPC: C07K14/50 ,  A61K45/06 ,  A61K47/60 ,  A61K38/18 ,  A61K47/64

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

公开(公告)号：US11344639B2

公开(公告)日：2022-05-31

申请号：US16305284

申请日：2017-05-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  David Donnelly ,  Dasa Lipovsek ,  Jochem Gokemeijer ,  Maria Jure-Kunkel ,  David Fabrizio ,  Martin C. Wright ,  Douglas Dischino ,  Samuel J. Bonacorsi, Jr. ,  Ralph Adam Smith ,  Virginie Lafont ,  Daniel Cohen ,  David K. Leung

IPC: A61K51/08 ,  C07B59/00 ,  C07K16/28

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

公开(公告)号：US11060085B2

公开(公告)日：2021-07-13

申请号：US16195295

申请日：2018-11-19

Applicant: Bristol-Myers Squibb Company

Inventor： Dasa Lipovsek

IPC: C40B30/04 ,  C12N15/10 ,  G01N33/68

Abstract: This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes.

公开(公告)号：US20200247873A1

公开(公告)日：2020-08-06

申请号：US16740248

申请日：2020-01-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dasa Lipovsek ,  Jonathan H. Davis

IPC: C07K14/78 ,  G01N33/68 ,  C07K16/24 ,  C07K16/28

Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

公开(公告)号：US10604556B2

公开(公告)日：2020-03-31

申请号：US15341623

申请日：2016-11-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jonathan Davis ,  Dasa Lipovsek ,  Ray Camphausen

IPC: C40B40/10 ,  C07K14/78 ,  C07K16/24 ,  C07K16/28 ,  C07K14/47 ,  G01N33/68 ,  C12N15/10 ,  A61K38/00

Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

公开(公告)号：US10442851B2

公开(公告)日：2019-10-15

申请号：US15127166

申请日：2015-03-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tracy S. Mitchell ,  Michael L. Gosselin ,  Dasa Lipovsek ,  Rex Parker ,  Ray Camphausen ,  Jonathan Davis ,  David Fabrizio

IPC: C07K14/78 ,  A61K47/64 ,  A61K38/00

Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

公开(公告)号：US10406251B2

公开(公告)日：2019-09-10

申请号：US15529260

申请日：2015-11-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  David Donnelly ,  Dasa Lipovsek ,  Jochem Gokemeijer ,  Maria N. Jure-Kunkel ,  David Fabrizio ,  Martin C. Wright ,  Douglas Dischino ,  Samuel J. Bonacorsi, Jr. ,  Ralph Adam Smith ,  Virginie Lafont ,  Daniel Cohen

IPC: A61K51/08 ,  C07K14/78 ,  G01N33/60 ,  G01N33/68 ,  G01N33/574

Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.

公开(公告)号：US20190256570A1

公开(公告)日：2019-08-22

申请号：US16287342

申请日：2019-02-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: C07K14/64 ,  C07K1/107

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US10377806B2

公开(公告)日：2019-08-13

申请号：US15979881

申请日：2018-05-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  Daniel Cohen ,  Ranjan Mukherjee ,  Timothy P. Reilly ,  Rose C. Christian ,  Dasa Lipovsek ,  Ray Camphausen ,  John Krupinski

IPC: A61K38/18 ,  C07K14/50 ,  A61K45/06 ,  A61K47/60 ,  A61K47/64 ,  A61K38/00

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.